Emergent Biosolutions (EBS) AI Stock Analysis

• Market Cap: $539.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): 7.9
• Beta (1Y): 3.04
• Revenue Growth: -29.91%
• EPS Growth: N/A
• Country: US
• Employees: 900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.06
• Shares Outstanding: 52,519,962
• 10 Day Avg. Volume: 2,092,351
• 30 Day Avg. Volume: 1,261,694
• PEG Ratio: 0.04
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 0.49
• P/FCF Ratio: 14.15
• Enterprise Value/Market Cap: 1.71
• Enterprise Value/Revenue: 1.09
• Enterprise Value/Gross Profit: 2.21
• Enterprise Value/Ebitda: 2.83
• 1Y Price Target: $15.00
• Price Target Upside: 47.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.27
• Revenue Forecast (FY): $799.07M

• Rating: 71 Outperform
• Price Target: $11.50 ▲(13.19% Upside)

Emergent Biosolutions' overall stock score is driven by strong earnings call results and positive technical analysis. The company has shown resilience in profitability and cash flow management, despite revenue challenges. Valuation metrics suggest the stock is undervalued, providing potential for future growth. However, high leverage and revenue decline remain concerns that need addressing.

Positive Factors

Cash Flow Management

Strong cash flow performance with a high free cash flow growth rate indicates efficient cash generation, supporting long-term financial stability.

International Revenue Growth

Increasing international sales diversify revenue streams and reduce reliance on domestic markets, enhancing growth prospects.

Naloxone Business Growth

Continued growth in the naloxone business strengthens market leadership and supports revenue stability in a critical product segment.

Negative Factors

High Leverage

Significant leverage poses financial risks, potentially limiting flexibility and increasing vulnerability to economic downturns.

Revenue Decline

Declining revenues due to divestitures and market variability can impact long-term growth and profitability.

Market Variability in Canada

Dependence on variable market conditions in Canada introduces revenue unpredictability, affecting financial planning.

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Emergent BioSolutions generates revenue through multiple streams, primarily from the sale of its vaccines and therapeutics in the Biodefense segment, which includes products like anthrax vaccines and botulinum antitoxin. The company also earns revenue from its Commercial segment, which focuses on providing contract development and manufacturing services for various pharmaceutical clients. Significant partnerships with government agencies, such as the U.S. Department of Health and Human Services, along with collaborations with private sector entities, contribute to a steady flow of contracts and funding, particularly for public health preparedness initiatives. Additionally, EBS benefits from licensing agreements and the commercialization of its proprietary products, which further bolster its earnings.

Emergent Biosolutions Financial Statement Overview

Summary

Emergent Biosolutions has demonstrated resilience in improving profitability and cash flow metrics despite facing revenue declines. The company's strong gross and net profit margins, along with improved cash flow ratios, are positive indicators. However, the high debt-to-equity ratio and declining revenue growth rate are areas of concern that could impact future financial stability.

Income Statement

Emergent Biosolutions has shown a significant decline in revenue over the TTM period, with a negative revenue growth rate of -11.85%. However, the company has improved its profitability metrics, with a gross profit margin of 49.13% and a net profit margin of 16.49% in the TTM, indicating strong cost management. The EBIT and EBITDA margins have also improved significantly, reflecting operational efficiency. Despite these improvements, the overall revenue decline is a concern.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 1.25, indicating significant leverage, which could pose financial risks. However, the return on equity has improved to 26.83% in the TTM, suggesting effective use of equity to generate profits. The equity ratio is moderate, reflecting a balanced asset structure. Overall, while profitability has improved, the high leverage remains a concern.

Cash Flow

Emergent Biosolutions has demonstrated strong cash flow performance with a significant free cash flow growth rate of 64.20% in the TTM. The operating cash flow to net income ratio is 1.33, indicating efficient cash generation relative to net income. The free cash flow to net income ratio is also strong at 91.72%, suggesting robust cash flow management. These metrics highlight the company's ability to generate cash despite revenue challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	846.20M	1.04B	1.05B	1.12B	1.77B	1.58B
Gross Profit	415.70M	375.40M	360.00M	473.00M	793.20M	863.10M
EBITDA	324.70M	53.40M	-47.00M	15.70M	504.20M	609.20M
Net Income	139.50M	-190.60M	-760.50M	-211.60M	219.50M	305.80M
Balance Sheet
Total Assets	1.42B	1.39B	1.82B	3.17B	2.96B	2.88B
Cash, Cash Equivalents and Short-Term Investments	267.30M	99.50M	111.70M	642.60M	576.10M	621.30M
Total Debt	667.80M	676.10M	860.20M	1.41B	841.00M	874.80M
Total Liabilities	880.90M	906.90M	1.17B	1.78B	1.34B	1.44B
Stockholders Equity	536.20M	482.80M	649.30M	1.38B	1.62B	1.45B
Cash Flow
Free Cash Flow	155.00M	35.80M	-257.90M	-149.90M	96.10M	395.00M
Operating Cash Flow	169.00M	58.70M	-206.30M	-34.10M	321.10M	536.00M
Investing Cash Flow	217.30M	125.20M	212.30M	-381.30M	-225.00M	-151.00M
Financing Cash Flow	-186.60M	-190.00M	-535.70M	481.20M	-141.00M	69.50M

Emergent Biosolutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Positive. The current price of 10.16 is above the 20-day moving average (MA) of 9.99, above the 50-day MA of 9.10, and above the 200-day MA of 7.41, indicating a bullish trend. The MACD of 0.40 indicates Positive momentum. The RSI at 52.31 is Neutral, neither overbought nor oversold. The STOCH value of 24.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EBS.

Emergent Biosolutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	74 Outperform	$1.13B	9.00	18.32%	―	1.37%	-18.10%
SIGA	72 Outperform	$582.87M	7.09	43.61%	―	3.86%	-2.60%
EBS	71 Outperform	$539.38M	7.85	13.92%	―	-29.91%	―
ANIP	62 Neutral	$1.96B	―	-2.82%	―	38.68%	-160.14%
DVAX	58 Neutral	$1.21B	―	-7.14%	―	26.73%	-310.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	46 Neutral	$981.78M	―	-15.57%	―	2.25%	-301.59%

Emergent Biosolutions Corporate Events

Emergent BioSolutions’ Earnings Call Highlights Strong Growth

Emergent BioSolutions’ recent earnings call painted a picture of optimism and robust financial health. The company reported a strong quarter, surpassing revenue and profitability expectations, and subsequently increased its financial guidance for the year. Despite some challenges, such as a decline in year-to-date revenues due to past divestitures and variability in Canadian sales, the overall sentiment remained positive, buoyed by significant growth in the naloxone business and international revenue.

Emergent BioSolutions Reports Strong Q3 2025 Results

Emergent BioSolutions Inc. is a biopharmaceutical company focused on providing medical countermeasures for biological threats and public health emergencies, operating primarily in the healthcare sector with a unique emphasis on products like vaccines and treatments for diseases such as anthrax and smallpox.

Emergent BioSolutions Raises Full-Year Revenue Guidance

On October 29, 2025, Emergent BioSolutions reported its financial results for the third quarter of 2025, with total revenues of $231.1 million, surpassing its guidance by $21 million. Despite a decrease in revenues compared to the previous year, the company experienced strong growth in its naloxone franchise, driven by NARCAN® Nasal Spray, and secured multiple contract modifications for its medical countermeasures products. The company raised its full-year revenue and profitability guidance, reflecting confidence in its product demand and strategic positioning in the market.

The most recent analyst rating on (EBS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Secures $56 Million Contract Modification

On September 5, 2025, Emergent BioSolutions received a $56 million contract modification from the U.S. Department of Health and Human Services to supply ACAM2000, a smallpox and mpox vaccine, under an existing 10-year contract. This modification underscores the ongoing collaboration between Emergent and the U.S. government to prioritize public health preparedness, with deliveries expected to begin in September 2025, contributing to projected sales of over $120 million for the year.

The most recent analyst rating on (EBS) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Advances Pediatric Botulism Antitoxin Study

Study Overview: Emergent BioSolutions is conducting a study titled ‘Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin.’ The study aims to verify pediatric dosing recommendations for the BAT product in children exposed to botulinum neurotoxin, ensuring safety and efficacy.

Emergent BioSolutions Secures $30M BARDA Contract Extension

On August 29, 2025, Emergent BioSolutions received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of CYFENDUS™, an anthrax vaccine. This contract, part of an ongoing agreement since 2016, underscores Emergent’s commitment to supporting U.S. national security priorities by ensuring the availability of medical countermeasures against anthrax threats. The deliveries are expected to start within the current calendar year and conclude by March 2026, highlighting Emergent’s strategic role in biodefense.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment

Emergent BioSolutions is spearheading a critical study titled ‘A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) for treating inhalational anthrax, a severe and potentially fatal condition. This research is significant as it will provide vital insights into the effectiveness of AIGIV during a major anthrax exposure event, focusing on patient survival and illness extent.

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Anthrax Treatment

Study Overview: Emergent BioSolutions is conducting an observational study titled ‘An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) in treating patients with systemic anthrax. This research is significant as it seeks to gather data on the extent of anthrax illness, survival rates, and serum concentrations of AIGIV and anthrax toxins in affected patients.

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer in Anthrax Treatment

Study Overview: Emergent BioSolutions is conducting a study titled ‘A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) in patients exposed to inhalational anthrax, particularly during a mass exposure event. This research is significant as it addresses a critical public health concern and fulfills a post-marketing requirement from the FDA.

Emergent BioSolutions’ AIGIV Study: A Key Development in Anthrax Treatment

Study Overview: Emergent BioSolutions is conducting an observational study titled ‘An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax.’ The study aims to evaluate the safety and clinical benefits of AIGIV (ANTHRASIL®) in patients with systemic anthrax, focusing on the extent of illness, survival rates, and pharmacokinetics of AIGIV. This research is significant as it fulfills a post-marketing requirement from the FDA to ensure the treatment’s efficacy and safety.

Emergent BioSolutions’ Earnings Call Highlights Strong Financial Performance

Emergent BioSolutions’ recent earnings call conveyed a generally positive sentiment, underscored by notable financial improvements and a promising outlook for international market growth. Despite facing some challenges with specific product sales, the company demonstrated resilience and adaptability in its core operations, which bodes well for its future performance.

Emergent BioSolutions Reports Improved Q2 2025 Results

Emergent BioSolutions Inc., a company specializing in medical countermeasures and life-saving solutions, reported its financial results for the second quarter of 2025. The company operates primarily in the biotechnology sector, focusing on products for health threats such as smallpox, anthrax, and opioid overdose emergencies.

Emergent BioSolutions Surpasses Q2 Revenue Expectations

Emergent BioSolutions reported its financial results for the second quarter of 2025, with total revenues of $140.9 million, surpassing guidance by $21 million. Despite a net loss of $12 million, the company showed significant improvements in profitability and margins compared to the previous year. The company raised its full-year profitability guidance and secured several government contracts, reinforcing its position in the medical countermeasures market.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.